Discovery of non-glycoside sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening.
暂无分享,去创建一个
Yi-Hui Peng | C. Chen | Y. Chao | Su-Ying Wu | Jian-Sung Wu | Jiun-Ming Wu | Chieh-Jui Hsieh | Szu-Huei Wu | M. Coumar | Jen‐Shin Song | Jinq-chyi Lee | Chi-Hui Tsai | Yu-Wei Liu | Jiun‐Ming Wu | Jian‐Sung Wu | Jinq-Chyi Lee
[1] G. Semenza,et al. Phlorizin as a probe of the small-intestinal Na+,D-glucose cotransporter. A model. , 1982, Biochimica et biophysica acta.
[2] R. DeFronzo,et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. , 1987, The Journal of clinical investigation.
[3] Yvonne C. Martin,et al. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists , 1993, J. Comput. Aided Mol. Des..
[4] D. Loo,et al. The sodium/glucose cotransporter (SGLT1). , 1993, Society of General Physiologists series.
[5] D. Loo,et al. Biophysical Characteristics of the Pig Kidney Na+/Glucose Cotransporter SGLT2 Reveal a Common Mechanism for SGLT1 and SGLT2* , 1996, The Journal of Biological Chemistry.
[6] Antihyperglycemic effect of T-1095 via inhibition of renal Na+-glucose cotransporters in streptozotocin-induced diabetic rats. , 2000, Biological & pharmaceutical bulletin.
[7] D. Porte,et al. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. , 2001, Diabetes/metabolism research and reviews.
[8] N. Lewis,et al. Phlorizin: a review , 2005, Diabetes/metabolism research and reviews.
[9] H. Kawahara,et al. Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. , 2007, Bioorganic & medicinal chemistry.
[10] W. Humphreys,et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. , 2008, Journal of medicinal chemistry.
[11] Yoshikazu Fujimori,et al. Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models , 2008, Journal of Pharmacology and Experimental Therapeutics.
[12] O. Marsenic. Glucose control by the kidney: an emerging target in diabetes. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[13] W. Washburn. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents , 2009, Expert opinion on therapeutic patents.
[14] W. Washburn. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. , 2009, Journal of medicinal chemistry.
[15] Yoshikazu Fujimori,et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. , 2009, European journal of pharmacology.
[16] Simona Distinto,et al. How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information , 2009, J. Chem. Inf. Model..
[17] Beat Ernst,et al. From carbohydrate leads to glycomimetic drugs , 2009, Nature Reviews Drug Discovery.
[18] H. Morita,et al. Cyclic Diarylheptanoids as Na+‐Glucose Cotransporter (SGLT) Inhibitors from Acer nikoense. , 2010 .
[19] H. Morita,et al. Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. , 2010, Bioorganic & medicinal chemistry.
[20] R. Henry,et al. SGLT2 inhibition — a novel strategy for diabetes treatment , 2010, Nature Reviews Drug Discovery.